Signum Surgical Receives €3.6 Million in Grant Funding to Support Launch of Therapy for Patients with a Common Colorectal Disease

Signum Surgical, a company dedicated to developing minimally invasive technologies to treat colorectal diseases, today announced the company has secured €3.6 million ($4 million) through two grant funding awards. The grants include €2.3 million from the European Union Horizon 2020 SME Instrument, and €1.3 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF). Funds from these grants will support regulatory and clinical programs leading to the commercialization of the company’s BioHealxTM device, which is designed to treat anal fistula, a painful colorectal condition that affects one in 5,000 people worldwide.